- Dapsone in Hidradenitis Suppurativa | PracticeUpdate
Looking for:
Dapsone therapy for hidradenitis suppurativa: a series of 24 patients |
- MeSH terms
Dapsone and hidradenitis suppurativa. Dapsone in Hidradenitis Suppurativa
-
Please update your settings with a valid address before to continue using PracticeUpdate. Close Back. Sign in. Join now. Follow us on:. Search PracticeUpdate Cancel. Dapsone appears to be an effective and well-tolerated treatment option for patients with HS. Crabtree, MD. Dermatology Written by. Hidradenitis suppurativa HS is a devastating disease that presents a significant treatment challenge. There is no one treatment that demonstrates efficacy in the majority of patients, and combinations of medical therapies as well as surgical interventions are often required.
As disease progresses, scarring and tunnels develop, making treatment more difficult. Prior to this study, the literature contained limited evidence to support dapsone as a treatment for HS, based on four case series with a total of 59 patients. In this article, Dr. The gender distribution was not typical for HS, with two-thirds men. The average age was 33 years, and The majority of the patients had mild or moderate disease, with All patients had failed a first-line therapy antibiotics, isotretinoin, surgery, colchicine.
Treatment with dapsone was started at 50 mg daily for 4 weeks, then titrated up to a dose of mg daily. Adverse events were generally mild and led to discontinuation in 5 patients. Almost two-thirds The presence of fistulae was significantly associated with a risk on non-response. This work demonstrates that dapsone may be a well-tolerated treatment for mild to moderate hidradenitis suppurativa, particularly in patients with the follicular phenotype and concomitant acne.
Dapsone is often used as an adjunctive treatment with other therapeutics in HS, which will require further study. This abstract is available on the publisher's site. Access this abstract now. Additional Info. National Library of Medicine. The use of dapsone in the treatment of HS is based on a few published cases successfully treated.
Objective: To evaluate the potential of dapsone treatment for HS in an open case series. Methods: An exploratory and retrospective review of case notes from HS patients treated with dapsone was performed. Patients were included irrespective of treatment outcome. Prior to the treatment the level of glucosephosphate dehydrogenase in the blood was tested for all patients. Results: A total of 24 HS patients were included and treated with dapsone.
None of the 4 cases with severe disease experienced improvement. Recurrence of disease at the cessation of treatment was described as rapid.
In this retrospective analysis, 56 patients with hidradenitis suppurativa HS were treated with dapsone 50 to mg daily, and Response to treatment varied by Hurley stage, with better response seen among those with milder disease, or Hurley stage I. The most frequent adverse effects included anemia, nausea, diarrhea, and headache, but none were severe. Hidradenitis suppurativa HS is a chronic inflammatory disease with a challenging treatment.
Current guidelines reserve dapsone as a third line agent for patients with mild to moderate HS. To our knowledge, only four small case series have been reported. The objective of this study was to assess the effectiveness and safety of dapsone in our clinical practice. A retrospective observational single-center study of 56 HS patients who underwent treatment with dapsone from May 1,to June 1,was performed.
Most of them had mild or moderate disease and belonged to LC2 follicular phenotype. All patients had been refractory to first-line treatments. No serious adverse reactions were detected. The median duration of treatment was 8 months. After multivariate analysis, an association was found between the presence of fistulous tracts and the risk of non-response to the drug. In four of the dapsone responders, oral retinoids were added to achieve a sustained response.
Limitations include the retrospective and non-controlled nature of this study. In conclusion, dapsone is an effective and well-tolerated option for long-term HS treatment, and in this series, it was mainly chosen for patients with LC2 phenotype. It would be interesting to study combination with retinoids and other management options. Allergy Clin. Property Value Status. We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site.
Please consider supporting PracticeUpdate by whitelisting us in your ad blocker. We have sent a message to the email address you have provided. If this email is not correct, please update your settings with your correct address.
The email address you provided during registration,does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate. Close Back. Sign in. Join now. Follow us on:. Search PracticeUpdate Cancel. Dapsone appears to be an effective and well-tolerated treatment option for patients with HS.
Crabtree, MD. Dermatology Written by. Hidradenitis suppurativa HS is a devastating disease that presents a significant treatment challenge. There is no one treatment that demonstrates efficacy in the majority of patients, and combinations of medical therapies as well as surgical interventions are often required. As disease progresses, scarring and tunnels develop, making treatment more difficult. Prior to this study, the literature contained limited evidence to support dapsone as a treatment for HS, based on four case series with a total of 59 patients.
In this article, Dr. The gender distribution was not typical for HS, with two-thirds men. The average age was 33 years, and The majority of the patients had mild or moderate disease, with All patients had failed a first-line therapy antibiotics, isotretinoin, surgery, colchicine.
Treatment with dapsone was started at 50 mg daily for 4 weeks, then titrated up to a dose of mg daily. Adverse events were generally mild and led to discontinuation in 5 patients. Almost two-thirds The presence of fistulae was significantly associated with a risk on non-response.
This work demonstrates that dapsone may be a well-tolerated treatment for mild to moderate hidradenitis suppurativa, particularly in patients with the follicular phenotype and concomitant acne.
Dapsone is often used as an adjunctive treatment with other therapeutics in HS, which will require further study. This abstract is available on the publisher's site. Access this abstract now. Additional Info. National Library of Medicine. Become a PracticeUpdate member now. Further Reading. Dermatology Dermatology.
Conclusion: Therapy with dapsone for patients with HS is possible, particularly in milder cases. The effect may be due to either antibacterial or anti-. Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by recurrent episodes of painful and disabling lesions in. Hidradenitis suppurativa (HS) is a chronic inflammatory disorder characterized by recurrent episodes of painful and disabling lesions in. Dapsone has been used for many years for HS and has. Conclusion: Therapy with dapsone for patients with HS is possible, particularly in milder cases. The effect may be due to either antibacterial or anti-. The email address you provided during registration,does not appear to be valid. The majority of the patients had mild or moderate disease, with Join now. Sign in. The average age was 33 years, and Access this abstract now.Background: Hidradenitis suppurativa HS is an inflammatory skin disease with a chronic intermittent course. HS is difficult to treat, and the evidence for the effect of most treatments consists of smaller open studies.
The use of dapsone in the treatment of HS is based on a few published cases successfully treated. Objective: To evaluate the potential of dapsone treatment for HS in an open case series. Methods: An exploratory and retrospective review of case notes from HS patients treated with dapsone was performed. Patients were included irrespective of treatment outcome. Prior to the treatment the level of glucosephosphate dehydrogenase in the blood was tested for all patients.
Results: A total of 24 HS patients were included and treated with dapsone. None of the 4 cases with severe disease experienced improvement. Recurrence of disease at the cessation of treatment was described as rapid. Limitations: The study is limited by lacking a control group. Conclusion: Therapy with dapsone for patients with HS is possible, particularly in milder cases.
The effect may be due to either antibacterial or anti-inflammatory effects of the drug, or both. Rapid recurrence after stopping treatment however suggests that anti-inflammatory effects may predominate.
The effect appears to be smaller than that reported with combination therapy using clindamycin and rifampicin. To clarify the true effect of dapsone future randomized controlled trials are necessary. Abstract Background: Hidradenitis suppurativa HS is an inflammatory skin disease with a chronic intermittent course.
Comments
Post a Comment